CounterPath (NASDAQ:CPAH) (TSE:CCV) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Wednesday.
Separately, Zacks Investment Research downgraded shares of CounterPath from a “buy” rating to a “hold” rating in a report on Tuesday, February 13th.
Shares of NASDAQ:CPAH opened at $2.55 on Wednesday. The stock has a market capitalization of $15.31, a P/E ratio of -4.05 and a beta of 0.08. CounterPath has a fifty-two week low of $1.75 and a fifty-two week high of $7.30.
In related news, Director Steven Bruk purchased 9,000 shares of the business’s stock in a transaction that occurred on Friday, March 16th. The shares were bought at an average cost of $3.22 per share, with a total value of $28,980.00. Following the acquisition, the director now owns 58,647 shares of the company’s stock, valued at $188,843.34. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 38.30% of the stock is currently owned by insiders.
CounterPath Company Profile
CounterPath Corporation designs, develops, markets, and sells software applications and related services in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. The company's software applications and related services enable enterprises and telecommunication service providers to deliver voice, video, and messaging and collaboration functionality over their Internet protocol and based networks.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for CounterPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CounterPath and related companies with MarketBeat.com's FREE daily email newsletter.